EveryONE Medicines
EveryONE Medicines is a pioneering biotechnology company focused on developing individualized antisense oligonucleotide (ASO) therapies to treat life-threatening neurodegenerative diseases in children caused by unique genetic variants. The company leverages proprietary AI-driven design and development processes to create a scalable library of ASO medicines, enabling rapid matching and custom therapy development for ultra-rare genetic mutations. EveryONE Medicines is also working closely with regulatory agencies, payers, treatment centers, and patient advocates to establish new regulatory pathways and reimbursement models for these personalized medicines. Their business model centers on delivering individualized medicines at scale, addressing a critical unmet need in rare pediatric diseases with no approved treatments, and advancing clinical trial strategies tailored to ultra-rare patient populations. The company operates globally with offices in the US and UK and has garnered significant media attention and partnerships in the rare disease and biotech sectors.
EveryONE Medicines
EveryONE Medicines is a pioneering biotechnology company focused on developing individualized antisense oligonucleotide (ASO) therapies to treat life-threatening neurodegenerative diseases in children caused by unique genetic variants. The company leverages proprietary AI-driven design and development processes to create a scalable library of ASO medicines, enabling rapid matching and custom therapy development for ultra-rare genetic mutations. EveryONE Medicines is also working closely with regulatory agencies, payers, treatment centers, and patient advocates to establish new regulatory pathways and reimbursement models for these personalized medicines. Their business model centers on delivering individualized medicines at scale, addressing a critical unmet need in rare pediatric diseases with no approved treatments, and advancing clinical trial strategies tailored to ultra-rare patient populations. The company operates globally with offices in the US and UK and has garnered significant media attention and partnerships in the rare disease and biotech sectors.